The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has drawn a clear line on CBD’s medical claims. Meanwhile, the Food Standards Agency (FSA) seems now to have softened its stance on the allowable levels of THC in CBD novel food products after it said it would have treated THC like a contaminant and its permitted levels in CBD products would have been below Home Office drug law levels.
The MHRA stated that if a company markets a product containing cannabidiol (CBD) and claims that it is medicinally effective, it will fall within the definition of a medicine under the Human Medicines Regulations 2012 and must hold marketing authorisation.